Lax 101d for Huntington's disease - horizon scanning review

Record ID 32002000539
Authors' objectives:

To summarise the current research evidence on Lax 101d for Huntington's disease (HD).

Authors' recommendations: - Clinical impact: HD is a devastating fatal condition with between 2,600 and 4,200 prevalent cases in England and Wales. If LAX-101d becomes available it is likely to have widespread usage within HD patients. There will also be many unanswered questions such as when is the optimum time to commence therapy, does therapy early in the disease produce better long-term outcomes, is there a sub-group who do not benefit etc. Further research will be necessary to clarify these issues. - Service impact: Little service impact would be expected in terms of administration of LAX-101d. If treatment with LAX-101d slows disease progression, the time until the patient requires full-time assistance or nursing home care may be delayed. However if the duration of the advanced stages of HD are increased the costs associated with full-time assistance or nursing home care may increase. - Additional factors: Current treatments are symptomatic only and do not alter the disease progression, so patients and carers are likely to welcome this treatment. There may be pressure to start treatment very early in the disease and possibly even in a speculative preventative capacity. - Financial and overall NHS impact: The cost of the treatment is currently unknown, as are any potential savings.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Humans
  • Huntington Disease
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.